References
- Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher JD. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol 2007;18: 243-6. https://doi.org/10.1007/s10840-007-9124-y
- Leitch A, McGinness P, Wallbridge D. Calculate the QT interval in patients taking drugs for dementia. BMJ 2007;335: 557. https://doi.org/10.1136/bmj.39020.710602.47
- Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can Pharm J 2016; 149: 139-52. https://doi.org/10.1177/1715163516641136
- Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991; 84: 1136-44. https://doi.org/10.1161/01.CIR.84.3.1136
- Morganroth J, Horowitz LN. Incidence of proarrhythmic effects from quinidine in the outpatient treatment of benign or potentially lethal ventricular arrhythmias. Am J Cardiol 1985; 56: 585-7. https://doi.org/10.1016/0002-9149(85)91015-X
- Soyka LF, Wirtz C, Spangenberg RB. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 1990;65: 74-81, 82-3.
- Litwin JS, Kleiman RB, Gussak I. Acquired (Drug-Induced) Long QT Syndrome. In: Electrical Diseases of the Heart. Edited by Gussak I, Antzelevitch C, Wilde AAM, Friedman PA, Ackerman MJ, Shen WK. London, Springer. 2008, pp 705-18.
- Frampton JE. Prucalopride. Drugs 2009; 69: 2463-76. https://doi.org/10.2165/11204000-000000000-00000
- Pratt CM, Singh SN, Al-Khalidi HR, Brum JM, Holroyde MJ, Marcello SR, et al. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol 2004; 43: 1211-6. https://doi.org/10.1016/j.jacc.2003.10.057
- ICH Harmonised Tripartite Guideline. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. E14. 2005. Available from www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf.